Vanda PharmaceuticalsLTS:0LKB -2.23%71 PB Ratio is 1.27 as of Jun. 24, 2026, which is 16% below its 10-year median of 1.52. GuruFocus rates LTS:0LKB with a GF Score™ of 71/100 and a GF Value™ of $5.57 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,233 Biotechnology companies, Vanda Pharmaceuticals ranks better than 76.32% on this metric.
The historical rank and industry rank for Vanda Pharmaceuticals's PB Ratio or its related term are showing as below:
LTS:0LKB'
s PB Ratio Range Over the Past 10 Years
Min: 0.36 Med: 1.52 Max: 6.81
Current: 1.24
During the past 13 years, Vanda Pharmaceuticals's highest PB Ratio was 6.81. The lowest was 0.36. And the median was 1.52.
LTS:0LKB's PB Ratio is ranked better than 76.32% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs LTS:0LKB: 1.24
During the past 12 months, Vanda Pharmaceuticals's average Book Value Per Share Growth Rate was -46.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -15.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 11.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vanda Pharmaceuticals was 106.90% per year. The lowest was -25.10% per year. And the median was 5.65% per year.
Back to Basics: PB Ratio
Vanda Pharmaceuticals (LTS:0LKB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vanda Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanda Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vanda Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vanda Pharmaceuticals (LTS:0LKB) has a PB Ratio of 1.27 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vanda Pharmaceuticals and its competitors. This is 16% below median its historical median of 1.52. Over the past decade, Vanda Pharmaceuticals' PB Ratio has ranged from 0.36 to 6.81. According to the industry distribution chart, Vanda Pharmaceuticals ranks #292 out of 1233 companies in the Biotechnology industry, placing it in the top 23.7%.
Is Vanda Pharmaceuticals' PB Ratio too high?
Vanda Pharmaceuticals' current PB Ratio of 1.27 is 16% below median its 10-year median of 1.52. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 6.81. The Biotechnology industry median PB Ratio is 2.83. Vanda Pharmaceuticals' value of 1.27 is 55.1% below this industry median. Based on the distribution chart, Vanda Pharmaceuticals ranks #292 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vanda Pharmaceuticals has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' PB Ratio compare to FBRX and ARTV?
According to the Biotechnology industry distribution chart, Vanda Pharmaceuticals ranks #292 out of 1233 companies for PB Ratio. This places Vanda Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.83. Vanda Pharmaceuticals' value of 1.27 is 55.1% below this benchmark. Historically, Vanda Pharmaceuticals' own PB Ratio has ranged from 0.36 to 6.81 over the past decade. While the company's 10-year median is 1.52 vs. the industry median of 2.83, Vanda Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vanda Pharmaceuticals's current PB Ratio of 1.27 is 55.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vanda Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanda Pharmaceuticals's current PB Ratio is 1.27, which is 16% below median its own 10-year median of 1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (LTS:0LKB) is currently considered Fairly Valued. The stock's GF Value™ is $5.57, compared to a current price of $5.91 — trading 6.1% above its estimated fair value. The current PB Ratio is 1.27, which is 16% below median its 10-year median of 1.52 and 55.1% below the Biotechnology industry median of 2.83. Vanda Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vanda Pharmaceuticals (LTS:0LKB), the current PB Ratio is 1.27 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanda Pharmaceuticals (LTS:0LKB) Overvalued in 2026?
Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued.
The current stock price of $5.91 is trading 6.1% above its estimated GF Value™ of $5.57.
GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.
Key valuation signals for LTS:0LKB:
PB Ratio: 1.27 (16% below median its 10-year median of 1.52)
GF Value™: $5.57 vs. price of $5.91 (6.1% above fair value)
Industry Position: 55.1% below the Biotechnology median (#292 of 1233)
No single metric tells the full story. See the LTS:0LKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
71GF Score
Get the complete analysis for LTS:0LKB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LKB has been successfully added to your 
